Data on PolyMedix Antimicrobial Polymers Being Presented at Annual Meeting of the American Chemical Society
Dr. Gregory Tew of the University of Massachusetts at Amherst, whose work is supported in part by a grant from PolyMedix, will be presenting two abstracts relating to the design of synthetic antimicrobial mimetics of host defense proteins, titled "Influence of lipid composition on membrane activity of synthetic antimicrobial oligomers", and a second abstract titled "Synthesis and activity of novel antimicrobial surfaces."
Dr. Brehm-Stecher of Iowa State University, whose work is supported in part by a grant from PolyMedix, will be presenting data, titled "Biomimetic polymer-based antimicrobial systems," showing the effect of a class of potentiating agents called sesquiterpenoids on the activity of certain of PolyMedix's antimicrobial polymer compounds. The sesquiterpenoids are compounds commonly used in many applications, such as food additives. PolyMedix has filed a patent application for the use of sesquiterpenoids to enhance the activity of its polymers.
The presentations will be made on Wednesday, August 22, and will be made available on the PolyMedix website at www.polymedix.com.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compounds - small molecule mimetics of human host-defense proteins - are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broad-spectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with our goal of developing an antagonist drug that is safer and easier to use than current approved therapy. PolyMedix plans to file its first IND application by the end of 2007 in anticipation of commencing human clinical trials for its antibiotic drug and its anticoagulant antagonist. For more information, please visit PolyMedix on its website at www.polymedix.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission, including those described under the heading "Risk Factors" in the Annual Report on Form 10-KSB originally filed by PolyMedix with the Securities and Exchange Commission on March 19, 2007 as well as the Registration Statement on Form SB-2 and Amendment No. 1 and Amendment No. 2 to such Registration Statement filed with the Securities and Exchange Commission on May 9, 2007, May 25, 2007, and July 24, 2007, respectively. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Lona Cornish, 484-598-2340
The Investor Relations Group
Erika Moran, 212-825-3210
Janet Vasquez, 212-825-3210
Posted: August 2007